Pharmaceutical companies turn to AI to speed up drug discovery
製藥公司轉向運用人工智慧以加速藥物開發
The pharmaceutical industry is currently undergoing a massive transformation as companies turn to Artificial Intelligence to tackle the "innovation crisis."
製藥行業目前正經歷一場巨大的變革，各大公司紛紛轉向人工智慧（AI），以解決「創新危機」。
AI is now acting as a "force multiplier," allowing researchers to analyze vast datasets to identify biological targets and design new molecules in days rather than months.
AI 現在充當著「倍增器」的角色，讓研究人員能夠分析龐大的數據集，在幾天內而非數月內識別出生物標靶並設計出新分子。
By using predictive modeling to filter out ineffective candidates early, companies can save substantial time and money.
透過使用預測模型儘早篩除無效的候選藥物，公司可以節省大量時間與成本。
While challenges like data quality, the "black box" nature of models, and a lack of specialized talent persist, the trend is undeniable.
儘管數據質量、模型的「黑箱」特性及專門人才短缺等挑戰依然存在，但這一趨勢已不可逆轉。
Newer "AI-first" biotech firms are forcing traditional giants to adapt or form strategic partnerships.
新興的「AI 先行」生物科技公司正迫使傳統巨頭調整步伐或達成策略合作。
